Mass General Brigham “One of the main limitations in the field of Alzheimer’s disease research and treatment is that it is extremely difficult to design medications that can pass the blood ...

The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...

A group of doctoral students at North Dakota State University are looking to change the future for caregivers of Alzheimer’s patients.

This novel design allows for modular customization ... and may help identify therapeutic targets for conditions like Alzheimer's." The research team's fluorescent cholesterol probes offer ...